What Cosentyx Treats
Cosentyx (secukinumab) is an injectable biologic that blocks interleukin-17A (IL-17A), a protein driving inflammation in autoimmune conditions. The FDA approves it for:
- Moderate to severe plaque psoriasis in adults and children 6+.
- Active psoriatic arthritis.
- Active ankylosing spondylitis (radiographic axial spondyloarthritis).
- Active non-radiographic axial spondyloarthritis.
- Active enthesitis-related arthritis (in kids 4+).
- Moderate to severe hidradenitis suppurativa.[1][2]
How Cosentyx Works
It targets IL-17A to reduce inflammation, scaling, and joint damage in these diseases. Administered via subcutaneous injection, typically starting with loading doses, then weekly or monthly maintenance.[1]
Common Side Effects Patients Report
Upper respiratory infections, diarrhea, and injection-site reactions occur most often. Serious risks include infections (e.g., tuberculosis reactivation), inflammatory bowel disease flares, and rare hypersensitivity. Patients with infections or IBD history need monitoring.[1][2]
Who Makes Cosentyx and How Much Does It Cost
Novartis manufactures and markets it. List prices exceed $5,000 monthly before insurance or discounts; patient assistance programs can lower costs.[1]
When Does Cosentyx Patent Expire
Key U.S. patents on secukinumab expire around 2031-2033, with some formulation patents later. Challenges from biosimilar developers like Alvotech and Formycon are ongoing.3
[1]: https://www.cosentyx.com
[2]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf